Penumbra (PEN) Stock Price, News & Analysis

Company Overview

Penumbra, Inc. (NYSE: PEN) is a global medical device company focused on developing innovative therapies to treat vascular and neurovascular diseases. The company designs, manufactures and markets a range of proprietary products used in interventional procedures, including aspiration systems for ischemic stroke, thrombectomy devices for peripheral arterial and venous occlusions, as well as embolization coils and plugs for hemorrhagic and aneurysm treatment. These offerings are supported by imaging and navigation tools aimed at improving procedural outcomes and patient safety.

Penumbra’s core product lines include the Penumbra System and the Indigo System, which utilize advanced aspiration and clot-retrieval technologies. The Lightning Stroke Platform integrates real-time, multispectral imaging for rapid triage in acute ischemic stroke cases. For peripheral vascular interventions, the company’s portfolio features a suite of access sheaths, catheters and guide wires designed for use in complex anatomies. Penumbra continually invests in R&D to expand its broad pipeline of neurology, peripheral and oncology-focused devices.

Founded in 2004 and headquartered in Alameda, California, Penumbra has built a commercial presence across North America, Europe, Asia-Pacific and Latin America. The company’s distribution network encompasses direct sales teams, strategic partnerships and a growing network of clinical specialists who collaborate with leading hospitals and imaging centers. Penumbra also supports clinical research initiatives worldwide to validate product performance and advance best practices in minimally invasive therapies.

Penumbra is guided by an experienced leadership team with deep expertise in medical technology innovation, regulatory affairs and global commercialization. Under the direction of its chief executive officer, the company remains committed to improving patient outcomes through continuous product enhancement, strategic alliances and rigorous clinical evaluation.

Key Stats

• Today's Range: $248.41 to $253.94
• 50-Day Range: $249.53 to $300.50
• 52-Week Range: $148.00 to $310.00
• Volume: 233,847 shs
• Average Volume: 453,066 shs
• Market Capitalization: $9.70 billion
• P/E Ratio: 75.91
• Dividend Yield: N/A
• Price Target: $302.40
• Consensus Rating: Moderate Buy

Penumbra Stock Analysis - MarketRank™

Penumbra scored higher than 95% of companies evaluated by MarketBeat, and ranked 187th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Penumbra has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 13 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Penumbra has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 36.51%

Earnings Growth

Earnings for Penumbra are expected to grow by 36.51% in the coming year, from $3.67 to $5.01 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Penumbra is 75.91, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.54.

Price to Earnings Ratio vs. Sector

The P/E ratio of Penumbra is 75.91, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.43.

Price to Earnings Growth Ratio

Penumbra has a PEG Ratio of 2.23. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Penumbra has a P/B Ratio of 8.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.10% of the float of Penumbra has been sold short.

Short Interest Ratio / Days to Cover

Penumbra has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Penumbra has recently increased by 17.83%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Penumbra does not currently pay a dividend.

Dividend Growth

Penumbra does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.7 / 5
• Environmental Score: -1.26

Percentage of Shares Shorted

4.10% of the float of Penumbra has been sold short.

Short Interest Ratio / Days to Cover

Penumbra has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Penumbra has recently increased by 17.83%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.06

News Sentiment

Penumbra has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Penumbra this week, compared to 11 articles on an average week.

Search Interest

9 people have searched for PEN on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Penumbra to their MarketBeat watchlist in the last 30 days. This is a decrease of -88% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Penumbra insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $31,582,595.00 in company stock.

Percentage Held by Insiders

Only 4.20% of the stock of Penumbra is held by insiders.

Percentage Held by Institutions

88.88% of the stock of Penumbra is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PEN Stock Analysis - Frequently Asked Questions

How have PEN shares performed this year?

Penumbra's stock was trading at $237.48 on January 1st, 2025. Since then, PEN stock has increased by 5.5% and is now trading at $250.54.

How were Penumbra's earnings last quarter?

Penumbra, Inc. (NYSE:PEN) released its quarterly earnings results on Wednesday, April, 23rd. The company reported $0.83 EPS for the quarter, topping analysts' consensus estimates of $0.66 by $0.17. The company's revenue was up 16.3% compared to the same quarter last year.
Read the conference call transcript.

How will Penumbra's stock buyback program work?

Penumbra's board initiated a stock buyback program on Tuesday, August 13th 2024, which authorizes the company to buy back $200,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 2.6% of its shares through open market purchases. Shares buyback programs are often a sign that the company's board of directors believes its shares are undervalued.

How do I buy shares of Penumbra?

Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Penumbra investors own include NVIDIA (NVDA), Meta Platforms (META), CrowdStrike (CRWD), Broadcom (AVGO), ServiceNow (NOW), Adobe (ADBE) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 4/23/2025
• Today: 7/03/2025
• Next Earnings (Estimated): 7/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:PEN
• CIK: 1321732
• Web: www.penumbrainc.com
• Phone: (510) 748-3200
• Fax: 510-748-3232
• Employees: 4,500
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $302.40
• High Stock Price Target: $340.00
• Low Stock Price Target: $245.00
• Potential Upside/Downside: +20.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.06
• Trailing P/E Ratio: 75.91
• Forward P/E Ratio: 68.27
• P/E Growth: 2.23
• Net Income: $14.01 million
• Net Margins: 3.41%
• Pretax Margin: 4.04%
• Return on Equity: 11.14%
• Return on Assets: 8.40%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 6.30
• Quick Ratio: 3.68

Sales & Book Value

• Annual Sales: $1.19 billion
• Price / Sales: 8.12
• Cash Flow: $2.90 per share
• Price / Cash Flow: 86.52
• Book Value: $29.99 per share
• Price / Book: 8.35

Miscellaneous

• Outstanding Shares: 38,730,000
• Free Float: 37,100,000
• Market Cap: $9.70 billion
• Optionable: Optionable
• Beta: 0.47